Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients rece...

Bibliografski detalji
Glavni autori:	Carroll, TM, Chadwick, JA, Owen, RP, White, MJ, Kaplinsky, J, Peneva, I, Frangou, A, Xie, PF, Chang, J, Roth, A, Amess, B, James, SA, Rei, M, Fuchs, HS, McCann, KJ, Omiyale, AO, Jacobs, B-A, Lord, SR, Norris-Bulpitt, S, Dobbie, ST, Griffiths, L, Ramirez, KA, Ricciardi, T, Macri, MJ, Ryan, A, Venhaus, RR, Van den Eynde, BJ, Karydis, I, Schuster-Böckler, B, Middleton, MR, Lu, X
Daljnji autori:	LUD2015-005 Project Team
Format:	Journal article
Jezik:	English
Izdano:	Cell Press 2023

Slični predmeti

Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment
od: VPCP Toledo, i dr.
Izdano: (2001-01-01)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
od: Ganesh Yadagiri, i dr.
Izdano: (2023-05-01)

Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy
od: M. Egyed, i dr.
Izdano: (2007-02-01)

Treatment of B-cells non-Hodgkin lymphomas with combined immunochemotherapy: ability to treatment optimization
od: N. V. Smirnova, i dr.
Izdano: (2015-12-01)

Expression profile of immunophenotypic marker molecules on B-lymphocytes in patients with chronic lymphocytic leukemia at the stages of immunochemotherapy
od: O. N. Selyutina, i dr.
Izdano: (2022-12-01)

Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphOCYtic leukemia
od: Tamara Pavlovna Zagoskina, i dr.
Izdano: (2010-03-01)

Programmed cell death in sympathetic neurons: a study by two-dimensional polyacrylamide gel electrophoresis using computer image analysis.
od: Amess, B, i dr.
Izdano: (1995)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
od: Jéssica Santos Cunha, i dr.
Izdano: (2021-03-01)

Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease
od: Bruno Mendes Roatt, i dr.
Izdano: (2014-06-01)

Right versus left thoracic approach esophagectomy for patients with neoadjuvant immunochemotherapy
od: Kexi Wang, i dr.
Izdano: (2025-12-01)

Neoadjuvant immunochemotherapy for pulmonary large-cell neuroendocrine carcinoma: case report
od: Chang Xu, i dr.
Izdano: (2024-04-01)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
od: Chaoyuan Liu, i dr.
Izdano: (2023-06-01)

Objectification of the method for glomerular filtration rate assessing in patients with diffuse large B-cell lymphoma during induction immunochemotherapy
od: A. S. Nozdricheva, i dr.
Izdano: (2024-04-01)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
od: Marta Rodríguez, i dr.
Izdano: (2022-08-01)

Neoadjuvant immunochemotherapy—a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma
od: Jiawei Chen, i dr.
Izdano: (2024-12-01)

Interleukin 15‐Presenting Nanovesicles with Doxorubicin‐Loaded Ferritin Cores for Cancer Immunochemotherapy
od: Yihui Zhai, i dr.
Izdano: (2025-01-01)

Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy
od: Nai-Wen Kang, i dr.
Izdano: (2017-12-01)

Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
od: Jiayi Geng, i dr.
Izdano: (2022-12-01)

Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation
od: Olayinka D. Ajayi, MD, i dr.
Izdano: (2019-06-01)

Reuse of structural domain–domain interactions in protein networks
od: Schuster-Böckler, B, i dr.
Izdano: (2007)

An introduction to hidden Markov models.
od: Schuster-Böckler, B, i dr.
Izdano: (2007)

Protein interactions in human genetic diseases.
od: Schuster-Böckler, B, i dr.
Izdano: (2008)

Visualizing profile-profile alignment: pairwise HMM logos.
od: Schuster-Böckler, B, i dr.
Izdano: (2005)

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
od: Zachary D. Epstein-Peterson, i dr.
Izdano: (2023-08-01)

Utilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy
od: Yoshikazu Hori, i dr.
Izdano: (2024-10-01)

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome
od: Soichiro Minami, i dr.
Izdano: (2024-07-01)

Clinical efficacy of neoadjuvant immunochemotherapy versus neoadjuvant chemotherapy for local advanced gastric adenocarcinoma
od: WANG Lei, i dr.
Izdano: (2024-10-01)

Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma
od: Chen Gu, i dr.
Izdano: (2024-05-01)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
od: Erik Gaitzsch, i dr.
Izdano: (2021-07-01)

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy
od: Zhangyi Luo, i dr.
Izdano: (2024-01-01)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
od: Yulong Chen, i dr.
Izdano: (2023-09-01)

Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia
od: Feng Zhang, i dr.
Izdano: (2022-11-01)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
od: Christine Schmitz, i dr.
Izdano: (2020-11-01)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
od: Kuwahara-Ota S, i dr.
Izdano: (2018-05-01)

The role of emotion regulation in the relationship between mindfulness and risk factors for disordered eating: a longitudinal mediation analysis
od: Osborne, EL, i dr.
Izdano: (2022)

Microscope-AOtools: A generalised adaptive optics implementation
od: Hall, N, i dr.
Izdano: (2020)

Unveiling the Power of Gut Microbiome in Predicting Neoadjuvant Immunochemotherapy Responses in Esophageal Squamous Cell Carcinoma
od: Le Liu, i dr.
Izdano: (2024-01-01)

Reduced intestinal‐to‐diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma
od: Lei Wang, i dr.
Izdano: (2024-11-01)

The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma
od: Man Sun, i dr.
Izdano: (2024-12-01)

Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma
od: Yaofei Jiang, i dr.
Izdano: (2024-10-01)